Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research note published on Tuesday morning,Benzinga reports. They currently have a $17.00 target price on the biotechnology company’s stock.

Several other brokerages also recently issued reports on ATRA. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price target for the company. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Stock Up 7.3 %

NASDAQ ATRA opened at $6.61 on Tuesday. The company has a market cap of $38.07 million, a price-to-earnings ratio of -0.26 and a beta of 0.49. Atara Biotherapeutics has a 52 week low of $5.40 and a 52 week high of $20.81. The business has a 50 day moving average price of $9.60 and a 200-day moving average price of $9.74.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, beating the consensus estimate of ($3.82) by $2.63. The firm had revenue of $32.75 million for the quarter, compared to the consensus estimate of $20.58 million. On average, equities research analysts anticipate that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp lifted its holdings in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. FMR LLC lifted its holdings in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares in the last quarter. Staley Capital Advisers Inc. lifted its holdings in Atara Biotherapeutics by 25.0% during the 4th quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company’s stock worth $666,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Vestal Point Capital LP lifted its holdings in Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.